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Objectives:Hemodialysis centers regularly survey arteriovenous (AV) accesses for signs of dysfunction. In this review, we
synthesize the available evidence to determine to what extent proactive vascular access monitoring affects the incidence of
AV access thrombosis and abandonment compared with clinical monitoring.
Methods:We searched electronic databases (MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science, and SCOPUS)
and sought references from experts, bibliographies of included trials, and articles that cited included studies. Two
reviewers independently assessed trial quality and extracted data. We used random effects meta-analysis to estimate the
pooled relative risk (RR) and 95% confidence interval (CI) across studies and conducted subgroup analyses to explain
heterogeneity. The I2 statistic was used to assess heterogeneity of treatment effect among trials.
Results: Nine studies (1363 patients) compared a strategy of surveillance vs clinical monitoring. A vascular intervention
to maintain or restore patency was provided to both groups if needed. Surveillance followed by intervention led to a
nonsignificant reduction of the risk of access thrombosis (RR, 0.82; 95% CI, 0.58-1.16; I2  37%) and access
abandonment (RR, 0.80; 95% CI, 0.51-1.25; I2  60%). Three studies (207 patients) compared the effect of vascular
interventions vs observation in patients with abnormal surveillance result. Vascular interventions after an abnormal AV
access surveillance led to a significant reduction of the risk of access thrombosis (RR, 0.53; 95% CI, 0.36-0.76) and a
nonsignificant reduction of the risk of access abandonment (RR, 0.76; 95% CI, 0.43-1.37).
Conclusion: Very low quality evidence yielding imprecise results suggests a potentially beneficial effect of AV access
surveillance followed by interventions to restore patency. This inference, however, is weak and will require randomized
trials of AV access surveillance vs clinical monitoring for rejection or confirmation. (J Vasc Surg 2008;48:48S-54S.)Patients with deteriorating renal function and end-
stage renal disease require vascular access that is safe, reli-
able, and associated with minimal complications. Although
autogenous arteriovenous (AV) access represents most
noncatheter vascular access in the world, 50% of some
United States dialysis patients with AV access receive a
prosthetic access.1
Hemodynamically significant outflow stenosis leading
to thrombosis is the most common cause of prosthetic
access abandonment. Early observational studies suggested
that correction of this stenosis could prevent thrombosis
and prolong access longevity.2,3 Investigators have since
conducted randomized controlled trials (RCTs) testing
whether serial measurements of blood flow vs usual clinical
From the Knowledge and Encounter Research Unit,a Division of Neph-
rology,b Division of Preventive Medicine,c Division of Vascular Surgery,d
Division of Endocrinology,e Mayo Clinic, Rochester; and Department of
Surgery, VA Medical Center, Georgetown and George Washington Uni-
versities.f
This review was funded by a contract from the Society of Vascular Surgery.
STATEMENTOFCONFLICTOF INTEREST: These authors report that
they have no conflicts of interest with the sponsor of this supplement
article or products discussed in this article.
Correspondence: M. Hassan Murad, MD, MPH, Division of Preventive,
Occupational and Aerospace Medicine, Mayo Clinic, 200 1st St SW,
Rochester, MN 55905 (e-mail: Murad.Mohammad@mayo.edu).
0741-5214/$34.00
Copyright © 2008 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2008.08.043
48Smonitoring would increase the longevity of AV access.
Some studies showed limited effect of surveillance on the
incidence of thrombosis or access longevity, whereas others
suggested surveillance could decrease complications and
reduce hospitalizations for prosthetic access dysfunc-
tion.2-4 These mixed research results notwithstanding, the
National Kidney Foundation, the Canadian Society of Ne-
phrology, and Caring for Australians with Renal Impair-
ment are among several professional organizations that
recommend frequent, regular surveillance with physical
examination and some form of serial access flow measure-
ments.5-7
Seeking to provide guidance in this area, the Society for
Vascular Surgery (SVS) formed a multispecialty committee
to formulate evidence-based clinical practice guidelines for
the care of patients who have a vascular access used for
chronic hemodialysis. Upon their request and to guide the
formulation of these guidelines, we conducted a systematic
review of the literature to identify and summarize the best
available evidence about the efficacy of access surveillance.
METHODS
The report of this protocol-driven systematic review was
approved by the SVS and adheres to the Quality of Reporting
of Meta-analyses (QUOROM) standards for reporting sys-
tematic reviews of RCTs and reporting Meta-analyses of Ob-
s how
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possible, we used the nomenclatures and definitions as pub-
lished in the “Recommended Standards for Reports Dealing
with Arteriovenous Hemodialysis Accesses” by the SVS.10
Eligibility criteria. Eligible studies were RCTs and
cohort studies that compared a group that underwent
active monitoring (the periodic evaluation of the vascular
access by using tests that may involve special instrumenta-
tion and for which an abnormal test result suggests the
presence of dysfunction) with a control group in which
patients received usual clinical monitoring and underwent
an interventional procedure only if they developed clinical
indications of access dysfunction. Usual clinical monitoring
could include physical findings of persistent swelling of the
arm, presence of collateral veins, prolonged bleeding after
needle withdrawal, or altered characteristics of pulse or
thrill in a graft.7
In addition, we included as a separate group studies in
which all participants had abnormal surveillance results and
were then randomly allocated to either vascular interven-
tion (angioplasty or surgical revision) or usual clinical mon-
itoring. The former studies provide evidence about the
efficacy of surveillance in general, whereas the latter studies
provide evidence regarding the efficacy of vascular interven-
tions in patients with abnormal surveillance results. Hence,
randomization was a necessary inclusion criterion only for
the efficacy of intervention studies. We included studies
that measured the outcomes of interest (thrombosis and
access abandonment) regardless of their language, sample
size, access type (autogenous or prosthetic), or duration of
patient follow-up.
Study identification. An expert reference librarian
(P. J. E.) designed and conducted the electronic search strat-
egy with input from study investigators with expertise in
conducting systematic reviews. To identify eligible studies, we
searched electronic databases (MEDLINE, EMBASE, Co-
chrane CENTRAL, Web of Science, and SCOPUS) through
March 2007 and actively monitored the literature for newer
publications thereafter. We also sought references from ex-
Fig 1. Flow chart showperts, bibliographies of included trials, and the Institute forScientific Information (ISI) Science Citation Index for publi-
cations that cited included studies (the strategy is available
from the authors upon request).
References were uploaded in a Web-based software
package developed for systematic review data management
(SRS, TrialStat Corp, Ottawa, Ontario, Canada). Paired
reviewers working independently screened all abstracts and
titles for eligibility. References that were deemed poten-
tially relevant were retrieved in full text and uploaded for
full text evaluation against eligibility criteria. The chance-
adjusted inter-reviewer agreement ( statistic) for study
eligibility was 0.78. Disagreements were resolved by con-
sensus (the two reviewers discussed the study and reached a
consensus) and by arbitration (a third reviewer adjudicated
the study) when disagreement continued.
Data collection. Two reviewers (E. T. C. and
A. Z. R.) working independently and using a standardized
form extracted descriptive, methodologic, and outcome
data from all eligible studies. We attempted to contact
authors of all included studies by e-mail to obtain missing
data. One study was translated to English.
Statistical analysis. For the meta-analyses, we pooled
relative risks (RR) from each trial using the DerSimonian-
Laird random effects model,11 estimated the 95% confi-
dence intervals (CIs) for each outcome, and calculated the
I2 statistic, which represents the proportion of variability
across trials that is not attributable to chance or random
error, but rather due to real differences in study design,
populations, or interventions.12 I2 values of 25%, 50%, and
75% indicate low, moderate, and high heterogeneity, re-
spectively. We used StatsDirect 2.5.4 software (StatsDirect
Statistical Software Ltd, England; 2005) for analysis.
To explain possible heterogeneity, we planned to con-
duct subgroup analyses based on patients’ gender, age, the
presence of diabetes mellitus, access type (autogenous vs
prosthetic), study design (RCT vs cohort study), and sur-
veillance method (duplex ultrasound imaging, intra-access
flow, or static venous dialysis pressure). We then tested for
studies were selected.effect-subgroup interactions,13 with   0.05.
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Study identification. Our search and selection proce-
dures are depicted in Fig 1. We found 14 eligible studies
(12 original studies and 2 reanalysis of published data).
Nine studies compared surveillance and intervention vs usual
clinical monitoring and intervention in 1363 participants
(mean sample size, 151) with a mean duration of 17 months
(range 6-28 months).14-22 The other three were trials of
patients who had abnormal surveillance results and were ran-
domly allocated to either vascular interventions (angioplasty
or surgical revision) or usual clinical monitoring; included
were 207 participants with a range of follow-up of 12 to 15
months.23-26 Table I summarizes the characteristics of the
included studies. Authors of six of the included studies re-
sponded to our queries for missing data.16,17,19-21,26
We excluded some surveillance studies in which all
patients underwent surveillance without a control group27
or studies of efficacy of vascular interventions in which
patients were partially randomized,28 because they did not
Table I. Study characteristics
First author, year Population Access typ
Mayer,15 1993 Chronic HD just had
access placed
Prosthetic
Lumsden,25 1997 Chronic HD with
50% stenosis
Prosthetic
Martin,24a 1999 Chronic HD with
50% stenosis
Prosthetic
Sands,21 1999a Chronic HD Autogenous,
prosthetic,
Sands,21 1999b Chronic HD Autogenous,
prosthetic,
Moist,16 2003 Chronic HD with
blood flow 650
Prosthetic
Ram,22 2003a Chronic HD Prosthetic
Ram,22 2003b Chronic HD Prosthetic
Dember,23 2004 Chronic HD with
SVPR 0.4
Prosthetic
Roca-Tey,20 2004 Chronic HD Autogenous,
prosthetic,
Tessitore,26 2004 Chronic HD with
50% stenosis
Autogenous
Malik,14 2005 Chronic HD Prosthetic
Plantinga,17 2006 Chronic HD Autogenous,
prosthetic,
Polkinghorne,18 2006 Chronic HD Autogenous
Robbin,19 2006 Chronic HD Prosthetic
DUS,Duplex ultrasound;HD, hemodialysis;NR, not reported; PTA, percu
pressure ratio; US, ultrasound.
aSubset analysis of Lumsden,25 1997.meet our inclusion criteria.Methodologic quality. The methodologic quality of
the included studies is summarized in Table II. Reviewers
had adequate chance-adjusted agreement in judging study
quality (  0.73). Overall, studies had poor reporting of
allocation concealment and blinding. Although blinding of
patients and care providers is often not feasible in surveillance
trials, blinding of data collectors and outcome assessors is
possible and highly desirable. The proportion of patients lost
to follow-up was10% in seven of 12 (58%) of the trials, and
the funding source was nonprofit in seven of 12 (58%).
Meta-analysis. Pooling results from the nine studies
that compared surveillance and intervention vs usual
clinical monitoring and intervention (Fig 2) demon-
strates that access surveillance led to a nonsignificant
reduction in the incidence of access thrombosis (7 stud-
ies: RR, 0.82; 95% CI, 0.58-1.16; I2  37%), and access
abandonment (6 studies: RR, 0.80; 95 % CI, 0.51-1.25;
I2  60%). Pooling results from the three studies of
patients who had abnormal surveillance results and were
Surveillance group
No. Method Surveillance frequency, days
35 DUS 90/180/365/730/1095
32 DUS, venous
pressure, urea
recirculation
60
8 DUS, venous
pressure, urea
recirculation
60
27 Blood flow/US Blood flow 30/US 180
35 SVP/US SVP 30/US 180
59 US dilution blood
flow
30
32 US dilution blood
flow
30
35 Duplex US 90
32 PTA, then SVPR 30
65 Qa US dilution 120
44 Access recirculation
initially, then US
dilution blood
flow/blood
pump flow
Recirculation & blood flow
90 days/blood pump
flow every HD
97 DUS 90
291 Urea recirculation,
dynamic and
static venous
pressure,
Doppler US
Weekly or more
68 Blood flow 30
65 US 120
s transluminal angioplasty; SVP, static venous pressure; SVPR, static venouse
68;
35
68;
35
90%;
10%
147;
216
taneourandomly allocated to either vascular intervention or
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 5S Casey et al 51Susual clinical monitoring (Fig 3) demonstrates a statisti-
cally significant reduction of the incidence of thrombosis
(RR, 0.53; 95% CI, 0.36-0.76; I  0%). Nevertheless,
there was no significant difference in the incidence of
access abandonment (3 studies: RR, 0.76; 95% CI, 0.43-
1.37; I2  70%).
Subgroup analyses. Subgroup analyses are summa-
rized in Table III. We found no significant effect-subgroup
interactions based on access type (prosthetic vs autoge-
nous), study design, or surveillance method (P  .05 for
both outcomes of access thrombosis and abandonment).
We found insufficient data to conduct the other planned
subgroup analyses.
DISCUSSION
Our findings. Our systematic review demonstrated a
trend toward benefit in the rate of thrombosis and access
survival in patients who underwent active access surveillance
Table I. Continued.
Cont
No. Control method
35 3/6/12/24/36 Months
32 Doppler US, venous pressure, urea recirculation
13 Doppler US, venous pressure, urea recirculation
41 No monthly monitoring, ultrasound 180 days
41 No monthly monitoring, US 180 days
53 Physical exam, dynamic venous pressure
34 Clinical criteria
34 Clinical criteria
32 Clinical criteria
94 Clinical criteria
33 Blood flow (Qa), blood pump flow (Qb), urea
recirculation, Kt/V
92 Clinical criteria
72 No access monitoring
67 Physical exam, dynamic venous pressure,
excessive bleeding
61 Physical exam, Kt/V, hemodialysis parameterscompared with patients who had usual clinical monitoring.Two of the included studies that compared a policy of
surveillance with that of usual clinical monitoring demon-
strated a significant reduction of access abandoment14 and
thrombosis.20 The first, by Malik et al,14 had methodologic
questions regarding randomization of patients, intention to
treat analysis, and widely varying times of ultrasoundDoppler
surveillance. The second study, by Roca-Tay et al,20 followed
patients with predominantly autogenous AV access (89%) and
reported an unusually high rate of thrombosis in the usual
clinical monitoring group of 17% compared with the group
undergoing AV access surveillance.20 This study must be
interpreted with caution because it is a preliminary report of a
5-year cohort study, and a full report has not been published.
In those patients who underwent an endovascular or
surgical procedure for a known stenosis and then were fol-
lowed upwith access surveillance or usual clinical monitoring,
the incidence of thrombosis was decreased; however, overall
graft life was equivalent between the two groups, perhaps due
oup
Frequency of control intervention Mean follow-up, days
NR 627
NR 462
NR 528
180 198
180 198
Every dialysis 450
Every dialysis 840
Every dialysis 840
1260 376
Every dialysis 365
1800 NR
392
Less than weekly or never 264
Every dialysis 558
Every dialysis 670rol grto restenosis shortly after the vascular intervention.29
R, Re
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ences from this review are limited by the very low quality of
the evidence available in the published literature. The qual-
ity of evidence supporting surveillance to prolong access
survival is downgraded30 due to methodologic limitations
of the primary studies (lack of bias protection measures),
imprecision (the CIs are wide enough to include important
Fig 2. Meta-analysis of the effect of surveillance on acces
treatment effect; squares and horizontal lines, point estim
study; diamonds, random-effects pooled relative risks. R
Table II. Study quality
Author, year Study design
Allocation
concealment Patients
Mayer,15 1993 Randomized NR NR
Lumsden,25 1997 Randomized NR No
Sands,21 1999 Randomized Yes No
Moist,16 2003 Randomized Yes Yes
Ram,22 2003 Randomized No No
Dember,23 2004 Randomized NR No
Tessitore,26 2004 Randomized Yes Yes
Malik,14 2005 Randomized NR NR
Polkinghorne,18
2006
Randomized No No
Robbin,19 2006 Randomized Yes No
Cohorts
representative
of typical
practice?
Exposure
adequately
ascertained?
Roca-Tey,20 2004 Prospective
cohort
Yes Yes
Plantinga,17 2006 Prospective
cohort
Yes Yes
NR, Not reported.benefit and harm from surveillance), and inconsistency(60% of the heterogeneity of the pooled estimate was not
attributed to chance).
Other limitations of the review are related to publica-
tion and reporting bias. Publication bias refers to the pref-
erential and prompt publication of significant results in
indexed and prominent journals; reporting bias refers to the
publication of the outcomes on which the intervention had
mbosis and abandonment. The vertical line indicates no
and associated 95% confidence intervals (CIs) for each
lative risk.
Blinding
Funding
Lost to
follow-up, %re givers
Outcome
assessors
Data
collectors
NR NR Unclear 0
NR NR Nonprofit 4.6
Yes No Nonprofit NR
Yes Yes Nonprofit 0
Yes No Nonprofit 0
NR No Nonprofit 9
No No Unclear 5
NR NR Nonprofit NR
Yes NR Unclear 22
Yes No Nonprofit NR
of
tcome
certained
start of
udy?
Cohorts are
comparable?
Outcome
ascertained
by
Yes Chart review Unclear 7.7
Yes Record
linkage
Nonprofit NRs thro
ates,Ca
NR
No
No
Yes
Yes
No
No
NR
Yes
Yes
Lack
ou
as
at
st
Yes
Noa significant effect without publication of nonsignificant
om-
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create an impression in favor of a particular technology.
Because our review is inconclusive owing to the imprecise
and negative studies, these biases appear not as problematic
Fig 3. Meta-analysis of the effect of vascular interven
results. The vertical line indicates no treatment effect; sq
confidence intervals (CIs) for each study; diamonds, rand
Table III. Subgroup analyses
Subgroup
Studies,
No.a RRb (95% CI)
P (interaction
test)
Access type
Access thrombosis
Autogenous 1 1.52 (0.48-4.85) .43
Prosthetic 6 0.94 (0.72-1.23)
Access abandonment
Autogenous 0 NA NA
Prosthetic 5 0.74 (0.45-1.23)
Study design
Access thrombosis
Randomized trials 6 0.90 (0.68-1.20) .06
Observational trials 1 0.24 (0.06-0.85)
Access abandonment
Randomized trials 5 0.74 (0.45-1.23) .28
Observational trials 1 1.36 (0.52-3.72)
Surveillance method
Access thrombosis
Duplex ultrasound 5 0.67 (0.36-1.24) .25
Intra-access flow 2 1.10 (0.62-1.96)
Static venous
dialysis pressure 0 NA
Access abandonment
Duplex ultrasound 3 0.70 (0.48-1.02) .98
Intra-access flow 5 0.91 (0.53-1.57)
Static venous
dialysis pressure 1 1.60 (0.79-3.99)
CI, confidence interval;NA, nonapplicable or incalculable;RR, relative risk.
aAnalysis conducted on the study design that provided the best evidence for
surveillance, which were studies that compared surveillance vs no surveillance.
bRandom effect method used for pooling relative risks; values1.0 indicate
that surveillance is beneficial.in this field, but their effect cannot be assessed reliably32and remains a limitation of any systematic review. Our
search for published and unpublished studies, although
thorough, does not completely exclude this possibility.
The strengths of this review are derived from having a
focused question, an explicit protocol of review with eligi-
bility criteria for studies, and a thorough and systematic
search strategy. We also used measures to decrease reviewer
bias, such as having independent reviewers select, evaluate,
and extract evidence in duplicate with adequate reproduc-
ibility, and contacting authors of the primary studies to
obtain complete and accurate data.
Implications for research and practice. The implica-
tions for practice are discussed in the accompanying clinical
practice guideline. Outcomes other than access thrombosis
and survival have also been reported in the literature and
may guide the decision about surveillance. A recent reanal-
ysis of one of the studies included in this report suggested
that although surveillance by duplex ultrasound imaging
combined with preemptive angioplasty did not prolong
prosthetic access life, reductions occurred in hospitalization
rates and costs as well as the total cost of access-related
care.4 However, this study was small, and cost-effectiveness
analyses in general tend to be highly affected by publication
bias.33 Further studies to determine both the relative effi-
cacy and the financial benefit of AV access surveillance vs
clinical monitoring are needed to strengthen the inferences
about the relative efficacy of this intervention.
CONCLUSIONS
Very low-quality evidence suggests that serial surveil-
lance of asymptomatic arteriovenous hemodialysis access
for the detection and treatment of stenosis may reduce the
risk of thrombosis and prolong access survival more than
usual clinical monitoring, but these comparisons were not
statistically significant. Large multicenter clinical trials of
vs observation in patients with abnormal surveillance
and horizontal lines, point estimates and associated 95%
effects pooled relative risks. RR, Relative risk.tions
uaressurveillance vs clinical monitoring appear necessary to es-
JOURNAL OF VASCULAR SURGERY
November Supplement 200854S Casey et altablish whether surveillance is cost effective in patients with
AV access for hemodialysis.
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